None
Conditions
Interventions
R1 group:The anesthesia effect was tested to determine whether the nerve block anesthesia or epidural anesthesia was successful. Remimazolam 4mg intravenously 60 seconds in Group R1.
R2 group:The anesthesia effect was tested to determine whether the nerve block anesthesia or epidural anesthesia was successful. Remimazolam 4.5mg intravenously 60 seconds in Group R2.
R3 group:The anesthesia effect was tested to determine whether the nerve block anesthesia or epidural anesthesia was successful. Remimazolam 5mg intravenously 60 seconds in Group R3.
R4 group:The anesthesia effect was tested to determine whether the nerve block anesthesia or epidural anesthesia was successful. Remimazolam 5.5mg intravenously 60 seconds in Group R4.
R5 group:The anesthesia effect was tested to determine whether the nerve block anesthesia or epidural anesthesia was successful. Remimazolam 6mg intravenously 60 seconds in Group R5.
Sponsors
The Second Affiliated Hospital of Xi'an Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 100 Years
Inclusion criteria
Inclusion criteria: Elderly patients = 65 years old who underwent elective surgery, regardless of gender; ASA grade I - III; Body mass index = 30kg / m2; The patient or authorized family member voluntarily signed and dated the informed consent, which was approved by the institutional review committee before the patient participated in the study; Patients were willing and able to comply with the study requirements and were able to follow up on the 7th day after operation.
Exclusion criteria
Exclusion criteria: Patients known to be allergic to benzodiazepines, flumazenil, opioids and naloxone, or patients with diseases that prohibit these drugs; Patients treated with benzodiazepines for a long time (such as insomnia, anxiety and spasm); Patients treated with opioids for a long time; Patients with positive drug abuse screening or positive serum ethanol; Patients with a history of drug or alcohol abuse in the past 2 years; Patients who received any investigational drug within 30 days before admission or less than 7 half lives, whichever is longer; Patients who have participated in the clinical trial of remimazolam; Patients who are unable to communicate well with the investigator or who are considered unsuitable by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Loss of consciousness time; | — |
Secondary
| Measure | Time frame |
|---|---|
| Maintenance time;Times of required assisted ventilation; | — |
Countries
China
Contacts
Public ContactYang Wanjun
The Second Affiliated Hospital of Xi'an Medical University
Outcome results
None listed